Semaglutide for PCOS

PCOS is a multifaceted hormonal disorder that manifests through a range of symptoms:

• Hyperandrogenism — Elevated levels of male hormones (androgens) cause acne, excess facial and body hair (hirsutism), and scalp hair thinning.
• Ovulatory dysfunction — Irregular or absent menstrual cycles result from disrupted ovulation, contributing to infertility.
• Polycystic ovaries — Multiple small follicles accumulate in the ovaries without reaching maturity.
• Insulin resistance — Present in 50–70% of women with PCOS, insulin resistance drives weight gain and worsens hormonal imbalances.
• Metabolic syndrome — Elevated risk for type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.

Insulin resistance is increasingly recognized as a central driver of PCOS pathophysiology. Elevated insulin stimulates ovarian androgen production, creating a vicious cycle that perpetuates symptoms. This is precisely why insulin-sensitizing therapies like semaglutide have attracted clinical interest.

Semaglutide addresses PCOS through several interconnected mechanisms:

Improved insulin sensitivity: As a GLP-1 receptor agonist, semaglutide enhances insulin secretion in a glucose-dependent manner and reduces hepatic glucose output. By lowering circulating insulin levels, it directly reduces the hormonal signal that drives excessive ovarian androgen production.

Weight reduction: Semaglutide promotes significant weight loss — averaging 10–15% of body weight in clinical trials. For women with PCOS, even a 5–10% reduction in body weight can restore ovulatory cycles and improve fertility outcomes.

Appetite regulation: Semaglutide acts on hypothalamic appetite centers to reduce hunger and food cravings. Many women with PCOS experience intense carbohydrate cravings driven by insulin resistance, and GLP-1 therapy can break this cycle.

Anti-inflammatory effects: Chronic low-grade inflammation is a feature of PCOS. GLP-1 receptor agonists have demonstrated anti-inflammatory properties that may further improve the metabolic and hormonal profile.

Hormonal rebalancing: By reducing insulin and promoting weight loss, semaglutide indirectly lowers androgen levels, potentially improving acne, hirsutism, and menstrual regularity.

Clinical evidence supporting GLP-1 receptor agonists for PCOS has grown substantially:

• Randomized controlled trials have shown that GLP-1 agonists (including liraglutide and semaglutide) significantly reduce body weight, fasting insulin, and androgen levels in women with PCOS compared to placebo.
• A 2023 meta-analysis of GLP-1 agonist trials in PCOS found significant improvements in BMI, waist circumference, fasting glucose, HOMA-IR (insulin resistance index), and testosterone levels.
• Fertility outcomes — Multiple studies report improved ovulation rates and menstrual regularity in women with PCOS treated with GLP-1 agonists, particularly when combined with lifestyle interventions.
• Comparative studies suggest GLP-1 agonists may outperform metformin — the traditional first-line insulin sensitizer for PCOS — in terms of weight loss and metabolic improvement.

While semaglutide is not yet FDA-approved specifically for PCOS, its approved indications for obesity and type 2 diabetes overlap heavily with PCOS comorbidities, making it a clinically relevant option.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Semaglutide is a prescription medication. Consult a qualified healthcare provider for PCOS treatment recommendations.

Semaglutide for PCOS typically follows a gradual dose escalation to minimize gastrointestinal side effects:

Subcutaneous injection protocol:

• Weeks 1–4: 0.25 mg once weekly (initiation dose)
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Week 13+: 1.7–2.4 mg once weekly (if tolerated and clinically indicated)

Many women with PCOS see meaningful improvements at the 1.0 mg weekly dose without needing to escalate further. The injection is administered once weekly, typically in the abdomen, thigh, or upper arm.

Important considerations:

• Semaglutide is contraindicated during pregnancy and should be discontinued at least 2 months before attempting conception.
• Common side effects include nausea, constipation, and diarrhea, which typically improve after the first 4–6 weeks.
• Adequate protein intake and strength training are recommended to preserve lean mass during weight loss.

The timeline for improvement varies by symptom:

• Weeks 1–4: Appetite reduction and decreased cravings are typically the first noticeable changes. Early weight loss begins.
• Months 1–3: Meaningful weight loss (3–7% of body weight). Fasting insulin levels begin to normalize. Some women notice improvement in menstrual regularity.
• Months 3–6: Significant weight loss (8–15%). Androgen levels decrease. Acne and hirsutism may begin improving. Ovulatory cycles may return in previously anovulatory women.
• Months 6–12: Maximum metabolic and hormonal benefits. Fertility improvements are most pronounced in this window. Inflammatory markers improve.

Consistent use combined with dietary optimization and regular exercise produces the best outcomes for PCOS management.

Semaglutide is a prescription medication available as branded products (Ozempic, Wegovy) through pharmacies. However, for research purposes, peptide-grade semaglutide is also available from specialized suppliers.

When sourcing research-grade semaglutide, prioritize:

• Third-party purity testing with certificates of analysis (COAs)
• Proper lyophilization and storage — semaglutide is sensitive to temperature and light
• US-based shipping with appropriate handling protocols

Ascension Peptides provides research-grade semaglutide with 99%+ purity verification, batch-specific COAs, and reliable US-based fulfillment. Their commitment to quality testing makes them a top choice for researchers studying GLP-1 peptides.